<?xml version="1.0" ?>
<GlossaryTerm id="CDR0000635691">
  <TermName>sequential AC/Taxol-Trastuzumab regimen</TermName>
  <TermPronunciation>(see-KWEN-shul … TAK-sol-tras-TOO-zoo-mab REH-jih-men)</TermPronunciation>
  <TermDefinition>
    <DefinitionText>An abbreviation for a chemotherapy combination used to treat breast cancer. It includes the drugs doxorubicin hydrochloride (Adriamycin) and cyclophosphamide, followed by treatment with paclitaxel (Taxol) and trastuzumab (Herceptin). Also called AC-T-T, AC-T-T regimen, and AC-TH regimen.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </TermDefinition>
  <MediaLink ref="CDR0000722831" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;sequential AC/Taxol-Trastuzumab regimen&quot;" language="en" id="_3"/>
  <MediaLink ref="CDR0000722832" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;régimen AC/Taxol-Trastuzumab en secuencia&quot;" language="es" id="_4"/>
  <SpanishTermName>régimen AC/Taxol-trastuzumab en secuencia</SpanishTermName>
  <SpanishTermDefinition>
    <DefinitionText>Nombre de una quimioterapia combinada que se usa para el tratamiento del cáncer de mama.   Incluye los medicamentos clorhidrato de doxorrubicina (Adriamycin) y ciclofosfamida, seguidos de tratamiento con paclitaxel (Taxol) y trastuzumab (Herceptin). También se llama AC-T-T, régimen AC-T-T y régimen AC-TH.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </SpanishTermDefinition>
  <DateFirstPublished>2009-02-20</DateFirstPublished>
</GlossaryTerm>
